Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 3Recurrence 2Lymphoproliferative Disorders 2Burkitt Lymphoma 2Neoplasms 1Neoplasm, Residual 1Lymphatic Diseases 1Immunoproliferative Disorders 1

Interventions

tisagenlecleucel 2fludarabine 2blinatumomab 2Cyclophosphamide 2zanubrutinib 1selinexor 1revumenib 1niraparib 1nilotinib 1ivosidenib 1imetelstat 1ibrutinib 1entrectinib 1dostarlimab 1brexucabtagene autoleucel 1avapritinib 1asciminib 1Standard of Care 1Paclitaxel 1Imatinib Mesylate 1GRN163L peptide 1Drug Therapy 1Dexamethasone 1Dasatinib 1Carboplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Recurrence × blinatumomab × Clear all
NCT02000427 2024-05-28

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

Amgen

Phase 2 Completed
45 enrolled 24 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Terminated
405 enrolled 27 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡